Maccura Biotechnology Co Ltd
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such a… Read more
Maccura Biotechnology Co Ltd - Asset Resilience Ratio
Maccura Biotechnology Co Ltd (300463) has an Asset Resilience Ratio of 0.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Maccura Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Maccura Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥50.20 Million | 0.63% |
| Total Liquid Assets | CN¥50.20 Million | 0.63% |
Asset Resilience Insights
- Limited Liquidity: Maccura Biotechnology Co Ltd maintains only 0.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Maccura Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Maccura Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Maccura Biotechnology Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Maccura Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.75% | CN¥60.06 Million | CN¥7.98 Billion | -3.08pp |
| 2023-12-31 | 3.83% | CN¥311.14 Million | CN¥8.12 Billion | -4.30pp |
| 2022-12-31 | 8.13% | CN¥663.72 Million | CN¥8.16 Billion | +5.23pp |
| 2017-12-31 | 2.90% | CN¥104.00 Million | CN¥3.58 Billion | -8.92pp |
| 2016-12-31 | 11.82% | CN¥319.00 Million | CN¥2.70 Billion | -15.16pp |
| 2015-12-31 | 26.98% | CN¥640.00 Million | CN¥2.37 Billion | -- |